This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
11-08 :: August 2011


nanotimes


Companies Facts


that can be implemented in diverse carriers such as coatings, plastics or liquids. These agents can be antimicrobial substances, flagrances, flavours and materials for fire protection.


“Our unique technology basically allows us to incor- porate every substance into products of our clients so that they display the desired controlled long-term ef- fect,” says Hermann Schirra, CEO of the company.


http://www.sarastro-nanotec.com S


electa Biosciences, Inc., a biopharmaceutical company developing an entirely new class of


targeted vaccines and immunotherapies, announced that Science Applications International Corpora- tion (SAIC) has awarded Selecta a subcontract to develop a targeted synthetic vaccine particle pro- duct for malaria. Under the terms of the award, the targeted Synthetic Vaccine Particle (tSVP™) vaccine for malaria will be developed by Selecta for testing in preclinical studies by SAIC collaborators. tSVP™ products are fully-integrated synthetic nanoparticle vaccines engineered to mimic the properties of na- tural pathogens to elicit a maximal immune response.


http://www.selectabio.com S


pire Corporation (NASDAQ: SPIR) reported reve- nues from continuing operations for the second-


quarter ended June 30, 2011 of $14.7 million, a 34% reduction from $22.3 million for the same quarter of 2010. Net income for the second-quarter of 2011 was $0.7 million, or $0.08 per share, compared to net income of $1.4 million, or $0.16 per share for


S


the second-quarter of 2010. Net income for the second-quarter of 2010 includes a net gain of $1.6 million or $0.19 per share from the Company’s Me- dical Products Business Unit which has been classi- fied as discontinued operations.


As of June 30, 2011, the Company had unrestricted cash and cash equivalents of $5.3 million.


Furthermore, Spire has been awarded a patent for its invention of a nanophotovoltaic (Nano-PV) device which, when applied to biological cells such as cancer, can control and/or limit their growth. The United States Patent and Trademark Office has issued Spire Corporation U.S. Patent No. 7,955,965 entitled “Nanophotovoltaic Devices.” Spire‘s inventi- on provides Nano-PV devices having sizes in a range of about 50nm to about 5µm, and a method for their fabrication. The devices functionalized to target spe- cific cells and then are selectively activated by light to generate an electrical charge to kill or interfere with cell growth.


Roger G. Little, Chairman, CEO, and co-inventor, said, “This being our third patent issued from our original invention, we have combined our understan- ding of photovoltaics with our experience in the bi- omedical field. We are excited to have received this patent and are enthusiastic that it makes an impact in medicine.”


http://www.SpireCorp.com


tarpharma Holdings Limited (ASX:SPL, OTCQX: SPHRY) announced two important developments in relation to the commercialisation of its VivaGel®


-


45


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103